In the Spotlight

Celebrating CCR Careers: Terri Armstrong, Ph.D., ANP-BC

Terri S. Armstrong, Ph.D., ANP-BC, FAAN, FAANP, has more than 30 years of experience caring for people with brain and spine tumors. After almost a decade in the Neuro-Oncology Branch, she is announcing her retirement.

Celebrating CCR Careers: Jonathan D. Ashwell, M.D.

For nearly 40 years at NCI, Jonathan D. Ashwell, M.D., has worked to understand the mechanisms and consequences of intracellular signaling, primarily in T cells, and how these contribute to disease. Now, the Chief of the Laboratory of Immune Cell Biology has announced his retirement.

Celebrating CCR Careers: Glenn Merlino, Ph.D.

Since first arriving at NCI in 1980, Glenn Merlino, Ph.D., has had a keen interest in unraveling the mechanistic underpinnings of cancer and how this knowledge could be used to improve patient care. Now, after decades of impactful research and mentorship, he is announcing his retirement.

Celebrating CCR Careers: David D. Roberts, Ph.D.

David D. Roberts, Ph.D., a biochemist who identified a new pathway that controls cell responses to stress and developed approaches to improve cancer therapy by shutting it down, announces his retirement from the NCI.

Celebrating CCR Careers: Mark Gilbert, M.D.

Mark Gilbert, M.D., has been a neuro-oncologist for nearly four decades, working to find better treatments for people with rare brain and spine tumors. After nearly a decade at CCR as Chief of the Neuro-Oncology Branch, he is announcing his retirement.

New Milestones publication now available

Every year, CCR makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This issue of our annual publication, Milestones, features 10 of our top scientific advances from the past year. These discoveries fall everywhere on the spectrum from basic science to clinical research, ranging from a change in our understanding of how cells replicate and divide to the first FDA-approved treatment for a rare cancer based on the results of an NCI trial. Our researchers have developed a novel drug delivery system inspired by bacterial spores, identified prognostic gene signatures for patients with different cancers and gathered data over 30 years to show that an immunotherapy essentially cures a rare precancerous disease.